Latest Breaking News On - Rezolute inc - Page 5 : comparemela.com

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13.02.2024 - Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access .

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

REDWOOD CITY, Calif., Jan. 24, 2024 Rezolute, Inc. , a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare.

Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket - argenx (NASDAQ:ARGX), Aclarion (NASDAQ:ACON)

Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS (Severe Low Back Pain)."

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today